IITRI is happy to share the promising news of one of our Sponsors, Ascletis Pharma, Inc. They just announced the Investigational New Drug (IND) application of ASC10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus, has been filed with the U.S. Food and Drug Administration (FDA). Our team here at IITRI was contracted to perform in vitro testing of ASC10 for antiviral effects against monkeypox.
“Currently there is no treatment approved for monkeypox virus infections globally. This IND filing of ASC10 for monkeypox in the U.S. will further broaden Ascletis’ pipeline portfolio in viral diseases, and may provide a solution to monkeypox virus infections.” said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis.
Here at IITRI, we look forward to continuing to work with Ascletis and other partners in the fight against diseases like monkeypox and COVID-19.
Read the full press release here.
Recent Comments